Influence of aromatase inhibitors on metabolic parameters in obese male patient

Shota Janjgava; Revazi Jamburia; Ana Davitashvili; Tekle Bakhtadze; Medea Zhgenti; Natia Goletiani

doi:10.1530/endoabs.99.EP772

EP772

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP772 | DOI: 10.1530/endoabs.99.EP772

ECE2024 Eposter Presentations Reproductive and Developmental Endocrinology (78 abstracts)

Influence of aromatase inhibitors on metabolic parameters in obese male patient

Shota Janjgava ¹ , Revazi Jamburia ¹ , Ana Davitashvili ¹ , Tekle Bakhtadze ¹ , Medea Zhgenti ¹ & Natia Goletiani ¹

Err

Author affiliations

¹National Institute of Endocrinology, Endocrinology, Georgia

Overview: Numerous epidemiological studies have demonstrated that low testosterone levels are linked to poor life quality and sexual quality, and that hypoestrogenic hypogonadism in obese male patients is connected with and predicts the development of metabolic syndrome and type 2 diabetes in the future. The purpose of the study was to demonstrate how aromatase inhibitors affected anthropometric traits, HOMA-IR, blood pressure, glycosylated hemoglobin level, and dyslipidemia in individuals with hyperechogenic and metabolic syndrome.

Resources and Techniques: 85 males with a BMI of 35.83±3.65 kg/m² and an age of 35±6.74 were randomly selected among 125 male patients with hypoestrogenism and obesity for a placebo-controlled trial. Patients were split up into three groups: 1) The first group received standard treatment. 2) The second group received standard aromatase inhibitor medication. 3) The third placebo group received standard care along with a placebo. We incorporated life style modification to all groups.

Results: We retook the diagnostic evaluations six months after starting treatment; lipid profile and free testosterone levels improved in all groups, but it was statistically significant in group II. All groups saw a drop in HbA1c, although group II saw the greatest improvement. All groups experienced a decrease in blood pressure, with comparable outcomes.

Conclusion: In obese male patients with hypoestrogenic hypogonadism, our study showed that increasing testosterone and adjusted estrogens can manage blood pressure, lipid profile, HbA1c, and HOMA.